Nonamplification	B:C0243095
ERBB2	B:C0242957
genomic	B:C0596611
alterations	I:C0596611
in	O
5605	O
cases	O
of	O
recurrent	B:C0278493
and	O
metastatic	B:C0278488
breast	I:C0278488
cancer	I:C0278488
:	O

An	O
emerging	O
opportunity	O
for	O
anti-HER2	B:C0243095
targeted	B:C3854476
therapies	I:C3854476
.	O

Activating	O
,	O
nonamplification	B:C0243095
ERBB2	B:C0242957
mutations	B:C0596611
(	O
ERBB2	B:C0678941
mutations	I:C0678941
)	O
are	O
not	O
detected	O
by	O
immunohistochemistry	B:C0021044
(	O
immunohistochemistry	B:C0021044
)	O
or	O
fluorescence	B:C0162789
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
(	O
fluorescence	B:C0162789
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
)	O
,	O
but	O
are	O
detected	O
by	O
DNA	B:C1294197
sequencing	I:C1294197
and	O
may	O
predict	O
clinical	B:C4055223
responses	I:C4055223
to	O
human	B:C1702024
epidermal	I:C1702024
growth	I:C1702024
factor	I:C1702024
receptor	I:C1702024
(	O
HER2	B:C1702024
)	O
-	O
targeted	B:C3854476
therapy	I:C3854476
.	O

The	O
authors	O
queried	O
5605	O
advanced	B:C0278488
/	I:C0278488
metastatic	I:C0278488
breast	I:C0278488
cancers	I:C0278488
(	O
advanced	B:C0278488
/	I:C0278488
metastatic	I:C0278488
breast	I:C0278488
cancers	I:C0278488
)	O
to	O
uncover	O
the	O
frequency	O
of	O
ERBB2	B:C0678941
mutations	I:C0678941
genomic	B:C0596611
alterations	I:C0596611
.	O

Clinical	B:C4055223
responses	I:C4055223
to	O
anti-HER2	B:C0243095
therapeutics	B:C0087111
were	O
identified	O
.	O

DNA	B:C0012854
was	O
extracted	O
from	O
40	O
µm	O
of	O
formalin	B:C2711483
-	I:C2711483
fixed	I:C2711483
paraffin	I:C2711483
-	I:C2711483
embedded	I:C2711483
(	I:C2711483
FFPE	I:C2711483
)	I:C2711483
sections	I:C2711483
.	O

Comprehensive	B:C0022885
genomic	I:C0022885
profiling	I:C0022885
(	O
Comprehensive	B:C0022885
genomic	I:C0022885
profiling	I:C0022885
)	O
was	O
used	O
to	O
evaluate	O
up	O
to	O
315	O
genes	B:C0017337
(	O
592	O
×	O
mean	O
coverage	O
depth	O
)	O
.	O

Results	O
were	O
analyzed	O
for	O
base	B:C1158746
substitutions	I:C1158746
,	O
short	B:C1956002
indels	I:C1956002
,	O
copy	B:C2717926
number	I:C2717926
changes	I:C2717926
,	O
and	O
selected	B:C0017287
rearrangements	I:C0017287
.	O

Of	O
5605	O
cases	O
,	O
698	O
(	O
12.5	O
%	O
)	O
featured	O
ERBB2	B:C0242957
alterations	B:C0596611
,	O
including	O
596	O
(	O
10.6	O
%	O
)	O
ERBB2	B:C0242957
amplifications	B:C0017256
(	O
ERBB2	B:C0017256
amplifications	I:C0017256
)	O
and	O
138	O
(	O
2.4	O
%	O
)	O
ERBB2	B:C0678941
mutations	I:C0678941
;	O
38	O
cases	O
(	O
0.7	O
%	O
)	O
had	O
co-occurring	O
ERBB2	B:C0017256
amplifications	I:C0017256
and	O
ERBB2	B:C0678941
mutations	I:C0678941
.	O

ERBB2	B:C0678941
mutations	I:C0678941
predominantly	O
affected	O
the	O
kinase	B:C0031727
(	O
124	O
cases	O
;	O
90	O
%	O
)	O
or	O
extracellular	B:C0521119
(	O
15	O
cases	O
;	O
11	O
%	O
)	O
domains	B:C1517050
.	O

Both	O
primary	B:C0678222
BC	I:C0678222
(	O
52	O
cases	O
;	O
38	O
%	O
)	O
and	O
metastatic	O
site	O
biopsies	B:C0005558
(	O
86	O
cases	O
;	O
62	O
%	O
)	O
were	O
found	O
to	O
harbor	O
ERBB2	B:C0678941
mutations	I:C0678941
,	O
which	O
were	O
distributed	O
across	O
carcinoma	B:C0007097
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
(	O
69	O
cases	O
;	O
50	O
%	O
)	O
,	O
invasive	B:C1134719
ductal	I:C1134719
carcinoma	I:C1134719
(	O
invasive	B:C1134719
ductal	I:C1134719
carcinoma	I:C1134719
)	O
(	O
40	O
cases	O
;	O
29	O
%	O
)	O
,	O
invasive	B:C0279565
lobular	I:C0279565
carcinoma	I:C0279565
(	O
invasive	B:C0279565
lobular	I:C0279565
carcinoma	I:C0279565
)	O
(	O
27	O
cases	O
;	O
20	O
%	O
)	O
,	O
and	O
mucinous	B:C1334807
mBC	I:C1334807
(	O
2	O
cases	O
;	O
1	O
%	O
)	O
.	O

Genes	B:C0017337
commonly	O
coaltered	O
with	O
ERBB2	B:C0242957
were	O
tumor	B:C0079419
protein	I:C0079419
53	I:C0079419
(	O
tumor	B:C0079419
protein	I:C0079419
53	I:C0079419
)	O
(	O
49	O
%	O
)	O
;	O
phosphatidylinositol	B:C1335212
3	I:C1335212
-	I:C1335212
kinase	I:C1335212
catalytic	I:C1335212
subunit	I:C1335212
alpha	I:C1335212
(	O
PIK3CA	B:C1335212
)	O
(	O
42	O
%	O
)	O
;	O
cadherin	B:C0694872
1	I:C0694872
,	I:C0694872
type	I:C0694872
1	I:C0694872
(	O
CDH1	B:C0694872
)	O
(	O
37	O
%	O
)	O
;	O
MYC	B:C0086661
(	O
17	O
%	O
)	O
;	O
and	O
cyclin	B:C1413172
D1	I:C1413172
protein	I:C1413172
(	O
cyclin	B:C1413172
D1	I:C1413172
protein	I:C1413172
)	O
(	O
16	O
%	O
)	O
.	O

CDH1	B:C0694872
mutations	B:C0596611
were	O
enriched	O
in	O
ERBB2	B:C0678941
mutations	I:C0678941
advanced	B:C0278488
/	I:C0278488
metastatic	I:C0278488
breast	I:C0278488
cancers	I:C0278488
(	O
P<	O
0.0006	O
)	O
and	O
associated	O
with	O
recurrent	O
mBC	O
.	O

Selected	O
patients	O
with	O
ERBB2	B:C0678941
mutations	I:C0678941
,	O
without	O
ERBB2	B:C0017256
amplifications	I:C0017256
,	O
who	O
responded	O
to	O
anti-HER2	B:C0243095
targeted	B:C3854476
therapies	I:C3854476
are	O
presented	O
herein	O
.	O

Within	O
this	O
large	O
series	O
,	O
1.8	O
%	O
of	O
cases	O
harbored	O
ERBB2	B:C0678941
mutations	I:C0678941
,	O
which	O
are	O
undetectable	O
by	O
standard	B:C2936643
-	I:C2936643
of	I:C2936643
-	I:C2936643
care	I:C2936643
immunohistochemistry	B:C0021044
or	O
FISH	B:C0162789
tests	I:C0162789
.	O

Metastatic	B:C0278488
BC	I:C0278488
driven	O
by	O
ERBB2	B:C0678941
mutations	I:C0678941
respond	O
to	O
anti-HER2	B:C0243095
targeted	B:C3854476
therapies	I:C3854476
,	O
and	O
expanding	O
clinical	B:C0008976
trials	I:C0008976
designed	O
to	O
detect	O
ERBB2	B:C0678941
mutations	I:C0678941
by	O
Comprehensive	B:C0022885
genomic	I:C0022885
profiling	I:C0022885
and	O
optimize	O
targeted	B:C3854476
treatments	I:C3854476
are	O
warranted	O
.	O

